Graft versus host disease (GvHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.
DelveInsight's “Graft versus host disease (GVHD) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Graft versus host disease (GVHD), historical and forecasted epidemiology as well as the Graft versus host disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of the Graft versus host disease Market report:
- The GvHD market size in the 7MM is expected to change during the study period 2018–2030, at a CAGR of 15.9%.
- In 2020, the 7MM reported 24,049 allogeneic cases, with a CAGR projecting an increase in cases by 2030. The United States accounted for 9,857 allogeneic cases in 2020, representing the highest percentage, of all allo-HSCT in the 7MM.
- GvHD is categorized into two types: aGvHD and cGvHD.
- In 2020, acute GvHD cases accounted for 11,638, while chronic cases accounted for 7,854. In the 7MM, the aGvHD and cGvHD cases are expected to rise to by 2030 during the forecast period, i.e., 2021–2030.
- Germany has the highest number of cases of GvHD by type (acute and chronic) among the EU-5 nations, with 2,984 in 2020.
- In the event of GvHD, corticosteroids are the first line of treatment; however, secondary data demonstrate that up to 40%-60% of all patients will be refractory to steroids. As per DelveInsight’s analysis, around 3,278 cases of cGvHD treated in first-line in the United States in 2020
- The mortality-adjusted treatment rate is used to estimate the number of living patients who are receiving treatment or who will be eligible for treatment. In 2020, the 7MM mortality adjusted treated aGvHD patients were 9,951 in first-line.
The key players in the GvHD market are:
- Imbruvica
- Temcell HS
- Incyte Corporation
- Enlivex Therapeutics
- Kiadis Pharma
- OncoImmune
- And Many Others
GvHD has two types Acute GvHD and Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. While Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects the liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucous or saliva.
Acute GVHD is staged and graded (grade I-IV) by the number and extent of organ involvement. While Chronic GvHD is staged according to a new clinical scoring system on a four-point scale (0-3) with 0 representing no involvement, 1 representing mild involvement (no significant impairment of daily living), 2 representing moderate involvement (significant impairment of daily living) and 3 representing severe impairment (major disability).
“According to Delveinsight, No significant difference was found in incidence of GvHD among male and female”
The launch of the emerging therapies is expected to significantly impact Graft versus host disease (GvHD) treatment scenario in the upcoming years:-
Graft versus host disease therapies covered:
- Imbruvica
- Temcell HS
- Ruxolitinib
- Itacitinib
- Allocetra
- ATIR101
- CD24Fc
- And Many Others
Table of contents:
- Key Insight
- Executive Summary of Graft Versus Host Disease (GvHD)
- Graft Versus Host Disease (GvHD) Market Overview at a Glance
- Disease Background and Overview: Graft Versus Host Disease (GvHD)
- Case Reports
- Graft Versus Host Disease (GvHD) Epidemiology and Patient Population
- United States Epidemiology
- EU5 Epidemiology
- Japan Epidemiology
- Current Graft Versus Host Disease (GvHD) Treatment and Medical Practices
- Unmet needs
- Graft Versus Host Disease (GvHD) Marketed Drugs
- Graft Versus Host Disease (GvHD) Emerging Drugs
- Graft Versus Host Disease (GvHD) 7MM Market Analysis
- United States
- EU-5 countries: Market Outlook
- Japan Market Outlook
- Graft Versus Host Disease (GvHD) Market Drivers
- Graft Versus Host Disease (GvHD) Market Barriers
- SWOT Analysis
- Reimbursement and market access
- Appendix
- DelveInsight Capabilities
- Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
